Valneva has reported encouraging six-month safety and antibody persistence data from the multi-centre Phase II trial, VLA1553 ...

Mediar Therapeutics has dosed the first subject in the Phase II WISPer trial of its investigational therapy, MTX-463, for ...

A phase 2 study of Vigil Neuroscience’s iluzanebart has missed its biomarker and efficacy endpoints, prompting the ...

Sempra's Port Arthur Phase 2 project in Texas has won U.S. approval to export liquefied natural gas to markets in Europe and ...

Disappointing results for iluzanebart come shortly after Vigil Neuroscience struck a buy-out deal with Sanofi, but analysts ...

Karnataka's cabinet has approved the establishment of Quantum Research Park phase-2 at IISc Bengaluru, with a government ...

According to the company, results showed “a meaningful clinical improvement in ocular surface health” and significance for ...